Quotient Sciences Acquires Arcinova

Read the press release here

Two new recruits join our Isotope Labelling team

Andrew Watson has joined Arcinova’s Isotope Labelling team as a Radiochemist and Zoë Wright has been appointed to the role of Synthetic Chemist. 

Andrew graduated from the University of Leeds with a Master of Chemistry degree and has since completed a PhD in Ruthenium catalysed transformations of alcohols at the University of Bath. He has held a number of post-doctorate research positions with the University of Canterbury, New Zealand, University of Bristol and most recently Cardiff University. 

Zoë has joined Arcinova from The Scripps Research Institute (TSRI) in California where she completed post-doctorate research on novel antiviral treatments for influenza. She has also completed a Master of Chemistry degree at the University of Oxford and holds a PhD in Organic Chemistry and Peptide Synthesis from University College London. 

In their new roles, Zoë and Andrew will focus on synthetic chemistry, where they’ll be responsible for synthesising and radiolabelling Active Pharmaceutical Ingredients (APIs).  

Arcinova’s team are highly experienced in the synthesis and analysis of 14C and stable-labelled compounds. We provide a range of radiolabelling solutions including: custom synthesis of 14C labelled compounds to support pre-clinical ADME studies; GMP synthesis of 14C labelled compounds for human AME studies; handling of 14C labelled gases and volatiles and synthesis of stable-labelled compounds. 

Commenting on his new appointment, Andrew Watson said: “I’m looking forward to utilising my expertise in chemical and radiochemical applications to provide our clients with the best service and consultancy to support their studies from development all the way through to delivery.” 

Zoë added: “It’s an exciting time for me to join the company and I’m looking forward to working with the team and applying my experience in both industrial and academic settings, helping our clients to achieve their objectives.”

Ian Shott, Executive Chairman and CEO of Arcinova, commented: “We are delighted to welcome Zoë and Andrew to the team - they are joining us at a truly exciting time in our development.

“Both Zoë and Andrew have a vast amount of experience which will add further scientific depth to the API department and the wider company as we grow.”

Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.